Recognition and Treatment of Neurologic Wilson's Disease

被引:15
作者
Lorincz, Matthew T. [1 ]
机构
[1] Univ Michigan Hlth Syst, Dept Neurol, Ann Arbor, MI 48109 USA
关键词
Wilson's disease; ceruloplasmin; copper; dysarthria; dystonia; tremor; parkinsonism; movement disorders; ZINC THERAPY; MANIFESTATIONS;
D O I
10.1055/s-0033-1334476
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
As Wilson's disease is both preventable and treatable, the diagnosis must not be missed. Despite this, it is usually misdiagnosed. Misdiagnosis and delay in treatment are clinically relevant because if left untreated, Wilson's disease progresses to hepatic failure or severe neurologic disability, and death. Those adequately treated have a normal life span. Wilson's disease is an autosomal recessive disease caused by mutations in the ATP7B gene. Mutations in ATP7B result in abnormal copper metabolism and subsequent toxic accumulation of copper. The clinical manifestations of neurologic Wilson's disease include variable combinations of dysarthria, dystonia, tremor, parkinsonism, ataxia, and choreoathetosis. Once the possibility of Wilson's disease is considered, diagnosis is straight forward. Currently available treatments, including zinc acetate and trientine, are generally well tolerated and effective.
引用
收藏
页码:538 / 543
页数:6
相关论文
共 23 条
[1]  
Akil M, 1995, Adv Neurol, V65, P171
[2]   Wilson's disease [J].
Ala, Aftab ;
Walker, Ann P. ;
Ashkan, Keyoumars ;
Dooley, James S. ;
Schilsky, Michael L. .
LANCET, 2007, 369 (9559) :397-408
[3]  
[Anonymous], 2001, WILSONS DIS CLIN GUI
[4]   Treatment of Wilson disease with ammonium tetrathiomolybdate - IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease [J].
Brewer, GJ ;
Askari, F ;
Lorincz, MT ;
Carlson, M ;
Schilsky, M ;
Kluin, KJ ;
Hedera, P ;
Moretti, P ;
Fink, MK ;
Tankanow, R ;
Dick, RB ;
Sitterly, J .
ARCHIVES OF NEUROLOGY, 2006, 63 (04) :521-527
[5]   WILSON DISEASE [J].
BREWER, GJ ;
YUZBASIYANGURKAN, V .
MEDICINE, 1992, 71 (03) :139-164
[6]   ORAL ZINC THERAPY FOR WILSONS-DISEASE [J].
BREWER, GJ ;
HILL, GM ;
PRASAD, AS ;
COSSACK, ZT ;
RABBANI, P .
ANNALS OF INTERNAL MEDICINE, 1983, 99 (03) :314-320
[7]   WORSENING OF NEUROLOGIC SYNDROME IN PATIENTS WITH WILSONS-DISEASE WITH INITIAL PENICILLAMINE THERAPY [J].
BREWER, GJ ;
TERRY, CA ;
AISEN, AM ;
HILL, GM .
ARCHIVES OF NEUROLOGY, 1987, 44 (05) :490-493
[8]   Prognostic significance of neurologic examination findings in Wilson disease [J].
Burke, James F. ;
Dayalu, Praveen ;
Nan, Bin ;
Askari, Fred ;
Brewer, George J. ;
Lorincz, Matthew T. .
PARKINSONISM & RELATED DISORDERS, 2011, 17 (07) :551-556
[9]   WILSONS-DISEASE AND EPILEPSY [J].
DENING, TR ;
BERRIOS, GE ;
WALSHE, JM .
BRAIN, 1988, 111 :1139-1155
[10]   WILSONS-DISEASE - A LONGITUDINAL-STUDY OF PSYCHIATRIC-SYMPTOMS [J].
DENING, TR ;
BERRIOS, GE .
BIOLOGICAL PSYCHIATRY, 1990, 28 (03) :255-265